Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis

Allergy and Asthma Proceedings

Volumn 32, Issue 3, 2011, Pages 221-229

  Salapatek, Anne Marie ^a   Lee, Joanne ^a   Patel, Deepen ^a   D'Angelo, Pina ^a   Liu, Jianhua ^a   Zimmerer Jr , Rupert O ^b   Pipkin, James D ^b  

^a Cetero Research   (Canada)

^b CyDex LC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BUDESONIDE; NOSE SPRAY; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL PRURITUS; NOSE ALLERGY; NOSE CONGESTION; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SNEEZING; SUSPENSION; TOTAL NASAL SYMPTOM SCORE; TREATMENT RESPONSE;

ADULT; ALLERGENS; AMBROSIA; BUDESONIDE; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PHTHALAZINES; POLLEN; PRURITUS; RHINITIS, ALLERGIC, SEASONAL; STEROIDS;

EID: 79956293591     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3444     Document Type: Article

References (29)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998. (Pubitemid 28553778)
2. Blaiss MS. Allergic rhinoconjunctivitis: Burden of disease. Allergy Asthma Proc 28:393-397, 2007.
3. Broide DH. The pathophysiology of allergic rhinoconjunctivitis. Allergy Asthma Proc 28:398-403, 2007.
4. Bernstein JA. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy Asthma Proc 31:365-369, 2010.
5. Broide DH. Allergic rhinitis: Pathophysiology. Allergy Asthma Proc 31:370-374, 2010.
6. Mahr TA. Therapy in allergic rhinoconjunctivitis: New horizons. Allergy Asthma Proc 28:404-409, 2007.
7. LaForce CF, Carr W, Tilles SA, et al. Evaluation of olopatadine dydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy Asthma Proc 31:132-140, 2010.
8. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
9. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 105:168-173, 2010.
10. Salapatek A, Patel P, Patel D, et al. Captisol®-enabled budesonide provides fast-, long- acting relief of allergic rhinoconjunctivitis symptoms: Evidence from a clinical trial shows significant total symptom score (TSS) and total ocular symptom score (TOSS) reduction with Captisol®-enabled budesonide compared to Rhinocort Aqua® and placebo in ragweed allergic patients studied in an environmental exposure chamber (EEC) model. Ann Allergy Asthma Immunol 102:A122, 2009.
11. Salapatek A, D'Angelo P, Bates M, et al. Novel combination product Captisol®-enabled budesonide+azelastine hcl provides fast, long-lasting relief of allergic rhinitis symptoms total nasal symptom score (TNSS) and individual nasal symptoms scores (NSS) in ragweed allergic patients studied in an environmental exposure chamber (EEC) model. J Allergy Clin Immunol 123:S130, 2009.
12. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system. Ann Allergy Asthma Immunol 87:474-481, 2001. (Pubitemid 34001035)
13. Egger M, Smith GD, and Phillips AN. Meta-analysis: Principles and procedures. Br Med J 315:1533-1537, 1997. (Pubitemid 27517188)
14. Maspero JF, Walters RD, Wu W, et al. An integrated analysis of the efficacy of fluticasone furoate nasal spray on individual nasal and ocular symptoms of seasonal allergic rhinitis. Allergy Asthma Proc 31:483-492, 2010.
15. Guidance for Industry. Allergic rhinitis: Clinical development programs for drug products (draft guidance). Rockville, MD: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2000.
16. Katial RK, Salapatek AM, and Patel P. Establishing the onset of action of intranasal corticosteroids: Is there an ideal study design? Allergy Asthma Proc 30:595-604, 2009.
17. Stanaland BE. Once-daily budesonide aqueous nasal spray for allergic rhinitis: A review. Clin Ther 26:473-492, 2004. (Pubitemid 38586449)
18. Primary Market Research from Giles & Associates Consultancy. Internal communicated report.
19. Petersen H, Kullberg A, Edsbäcker S, et al. Nasal retention of budesonide and fluticasone in man: Formation of airway mucosal budesonide-esters in vivo. Br J Clin Pharmacol 51:159-163, 2001. (Pubitemid 32216065)
20. CyDex pharmaceuticals. Captisol brochure. Lenexa, KS; 2008. Available online at www.abstracts.aapspharmaceutica.com/expoaaps06/Data/EC/Event/ Exhibitors/70/d8e6c738-cb86-4848-82b9-3f6cc2825a7b.pdf 2009; last accessed 2009.
21. Fukaya H, Iimura A, Hoshiko K, et al. A cyclosporin A/malto-syl-alpha- cyclodextrin complex for inhalation therapy of asthma. Eur Respir J 22:213-219, 2003. (Pubitemid 36986987)
22. Merkus FW, Verhoef JC, Romeijn SG, et al. Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats. Pharm Res 8:588-592, 1991.
23. Stella VJ, and He Q. Cyclodextrins. Toxicol Pathol 36:30-42, 2008.
24. Charman SA, Perry CS, Chiu FC, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci 95:256-267, 2006. (Pubitemid 43241969)
25. Egan TD, Kern SE, Johnson KB, et al. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol®) versus propofol in a lipid formulation (Diprivan): An electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 97:72-79, 2003. (Pubitemid 36736541)
26. McIntosh MP, Schwarting N, and Rajewski RA. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation. J Pharm Sci 93:2585-2594, 2004.
27. von Mach MA, Burhenne J, and Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 6:6, 2006.
28. Kim Y, Oksanen DA, Massefski W Jr, et al. Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci 87:1560-1567, 1998. (Pubitemid 28559642)
29. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 44:1117-1133, 2005. (Pubitemid 41483699)